REVB
Revelation Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.50M
P/E Ratio
—
EPS
$-23.95
Beta
-0.17
52W High
$44.16
52W Low
$1.06
50-Day MA
$1.41
200-Day MA
$5.45
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
0.89
PEG Ratio
—
About Revelation Biosciences Inc
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of immunological diagnostics and therapeutics for the prevention and treatment of disease. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $90.91M |
| EBITDA | $-9.04M |
| Operating Margin | 0.00% |
| Return on Equity | -131.40% |
| Return on Assets | -62.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.59 |
| Price-to-Book | 0.53 |
| Price-to-Sales (TTM) | 2.88 |
| EV/Revenue | - |
| EV/EBITDA | -1.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.72M |
| Float | $3.27M |
| % Insiders | 5.66% |
| % Institutions | 8.27% |
Analyst Ratings
Consensus ($19.25 target)
1
BuyData last updated: 4/9/2026